



RegCell's Corporate Highlights

RegCell is developing stable/functional epigenetically modified Tregs: a novel therapeutic platform with key advantages



Founded based upon world-class scientific leadership based on the discovery of Tregs by Scientific Founder Professor Shimon Sakaguchi, providing privileged biological insights



Recently awarded **\$60M grant to fund clinical POC in some autoimmune disorders**



IND ready – FIH platform validation trial in Pemphigus vulgaris will launch in mid 2025



S/F Epigen-Tregs recapitulate key Treg imprinting, and memory features leading to long-term persistence and can achieve infectious tolerance, antigen-driven expansion, de novo Treg expansion



The ability to copy autoantigen fingerprints – including unknown antigens – is a major point of competitive differentiation



Manufacturing process is efficient and does not require genetic manipulation leading to greater simplicity, lower cost and **easier commercialization**